Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

被引：0
|
作者：
Becker, Pamela S.
Estey, Elihu [2 ]
Petersdorf, Stephen
Hendrie, Paul C. [1 ]
Pagel, John M. [2 ]
Stirewalt, Derek
Shustov, Andrei
Storer, Barry E.
Appelbaum, Frederick R. [3 ]
机构：
[1] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1018 / 1018
页数：1
相关论文
共 50 条
  • [21] G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial
    Halpern, Anna B.
    Huebner, Emily M.
    Othus, Megan
    Scott, Bart L.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Gardner, Kelda M.
    Buckley, Sarah A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2017, 130
  • [22] Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: A multicenter, randomized control trial in southwest China
    Zhang, Xi
    Li, Yunlong
    Zhang, Yanqi
    Chen, Xinghua
    Zhang, Cheng
    Gao, Li
    Kong, Peiyan
    Liu, Yao
    Wen, Qin
    Zeng, Yunjing
    Wang, Qingyu
    Su, Yi
    Wang, Chunsen
    Wang, Sanbin
    Yuan, Zhong
    Gao, Lei
    LEUKEMIA RESEARCH, 2013, 37 (06) : 657 - 664
  • [23] Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Zeidner, Joshua F.
    Vincent, Benjamin G.
    Ivanova, Anastasia
    Moore, Dominic
    McKinnon, Karen P.
    Wilkinson, Alec D.
    Mukhopadhyay, Rupkatha
    Mazziotta, Francesco
    Knaus, Hanna A.
    Foster, Matthew C.
    Coombs, Catherine C.
    Jamieson, Katarzyna
    Van Deventer, Hendrik
    Webster, Jonathan A.
    Prince, Gabrielle T.
    DeZern, Amy E.
    Smith, B. Douglas
    Levis, Mark J.
    Montgomery, Nathan D.
    Luznik, Leo
    Serody, Jonathan S.
    Gojo, Ivana
    BLOOD CANCER DISCOVERY, 2021, 2 (06): : 616 - 629
  • [24] Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
    Motabi, Ibraheem H.
    Al Aoun, Shaima M.
    Al-Ammari, Maged
    Albtoosh, Belal M.
    Iqbal, Shahid
    Altaf, Syed Y.
    Tailor, Imran K.
    Alnoamani, Mohammed S.
    AlGhamdi, Mubarak S.
    Zaidi, Syed Z. A.
    AlShehry, Nawal F.
    Marei, Mohammed A.
    Alfayez, Mansour
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 720 - 723
  • [25] Successful Salvage Treatment With Clofarabine and Cytarabine In Relapsed/Refractory Acute Myeloid Leukemia
    Malato, Alessandra
    Acquaviva, Francesco
    Santoro, Alessandra
    Felice, Rosaria
    Magrin, Silvana
    Turri, Diamante
    Scime, Rosanna
    Di Bella, Raimondo
    Salemi, Domenico
    Fabbiano, Francesco
    BLOOD, 2013, 122 (21)
  • [26] G-CSF priming in acute myelogenous leukemia
    Murashige, N
    Kami, M
    Takaue, Y
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21): : 2071 - 2072
  • [27] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
  • [28] HIGH DOSE CYTARABINE, CLOFARABINE AND GEMTUZUMAB OZOGAMICIN (CLAC-MYL) IN RELAPSED OR REFRACTORY AML PATIENTS
    Scappini, B. S.
    Gianfaldoni, G.
    Susini, M. C.
    Fanci, R.
    Baldini, S.
    Fjerza, R.
    Mannelli, F.
    Longo, G.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 549 - 549
  • [29] CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous Leukemia: a modified combination chemotherapeutic combination
    Chen, Lin
    Yin, Qingsong
    Mi, Ruihua
    Wei, Xudong
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2291 - 2293
  • [30] Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML
    Uy, Geoffrey L.
    Rettig, Michael P.
    Fletcher, Theresa
    Riedell, Peter A.
    Stockerl-Goldstein, Keith E.
    Ghobadi, Armin
    Jacoby, Meagan
    Cashen, Amanda F.
    Romee, Rizwan
    Pusic, Iskra
    Abboud, Camille N.
    Schroeder, Mark A.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    BLOOD, 2017, 130
12345